EUPRAXIA PHARMACEUTICALS INC. Other Research and Development Expense
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Other Research and Development Expense of $1.83 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-03-13
| Period end | Other Research and Development Expense 12 month | Other Research and Development Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.83M 40-F · filed 2026-03-13 | |
| 2024-12-31 | $578.81K 40-F · filed 2026-03-13 | |
| 2023-12-31 | $472.19K 40-F · filed 2025-03-20 | $672.29K 40-F · filed 2024-04-01 |
| 2022-12-31 | $424.63K 40-F · filed 2024-04-01 |